Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes

dc.contributor.authorHendriks A. Emile J.
dc.contributor.authorMarcovecchio M. Loredana
dc.contributor.authorBesser Rachel E. J.
dc.contributor.authorBonifacio Ezio
dc.contributor.authorCasteels Kristina
dc.contributor.authorElding Larsson Helena
dc.contributor.authorGemulla Gita
dc.contributor.authorLundgren Markus
dc.contributor.authorKordonouri Olga
dc.contributor.authorMallone Roberto
dc.contributor.authorPociot Flemming
dc.contributor.authorSzypowska Agnieszka
dc.contributor.authorToppari Jorma
dc.contributor.authorBerge Thekla von dem
dc.contributor.authorZiegler Anette G.
dc.contributor.authorMathieu Chantal
dc.contributor.authorAchenbach Peter
dc.contributor.authorINNODIA consortium
dc.contributor.authorFr1daStudy Group and GPPAD Study Group
dc.contributor.organizationfi=InFLAMES Lippulaiva|en=InFLAMES Flagship|
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=lastentautioppi|en=Paediatrics and Adolescent Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organizationfi=väestötutkimuskeskus|en=Centre for Population Health Research (POP Centre)|
dc.contributor.organization-code1.2.246.10.2458963.20.42471027641
dc.contributor.organization-code1.2.246.10.2458963.20.68445910604
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id387237973
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/387237973
dc.date.accessioned2025-08-28T01:56:19Z
dc.date.available2025-08-28T01:56:19Z
dc.description.abstract<p><strong>Background/aim: </strong>Type 1 diabetes is an autoimmune disease that involves the development of autoantibodies against pancreatic islet beta-cell antigens, preceding clinical diagnosis by a period of preclinical disease activity. As screening activity to identify autoantibody-positive individuals increases, a rise in presymptomatic type 1 diabetes individuals seeking medical attention is expected. Current guidance on how to monitor these individuals in a safe but minimally invasive way is limited. This article aims to provide clinical guidance for monitoring individuals with presymptomatic type 1 diabetes to reduce the risk of diabetic ketoacidosis (DKA) at diagnosis.</p><p><strong>Methods: </strong>Expert consensus was obtained from members of the Fr1da, GPPAD, and INNODIA consortia, three European diabetes research groups. The guidance covers both specialist and primary care follow-up strategies.</p><p><strong>Results: </strong>The guidance outlines recommended monitoring approaches based on age, disease stage and clinical setting. Individuals with presymptomatic type 1 diabetes are best followed up in specialist care. For stage 1, biannual assessments of random plasma glucose and HbA1c are suggested for children, while annual assessments are recommended for adolescents and adults. For stage 2, 3-monthly clinic visits with additional home monitoring are advised. The value of repeat OGTT in stage 1 and the use of continuous glucose monitoring in stage 2 are discussed. Primary care is encouraged to monitor individuals who decline specialist care, following the guidance presented.</p><p><strong>Conclusions: </strong>As type 1 diabetes screening programs become more prevalent, effective monitoring strategies are essential to mitigate the risk of complications such as DKA. This guidance serves as a valuable resource for clinicians, providing practical recommendations tailored to an individual's age and disease stage, both within specialist and primary care settings.</p>
dc.identifier.eissn1520-7560
dc.identifier.jour-issn1520-7552
dc.identifier.olddbid208306
dc.identifier.oldhandle10024/191333
dc.identifier.urihttps://www.utupub.fi/handle/11111/57682
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/full/10.1002/dmrr.3777
dc.identifier.urnURN:NBN:fi-fe2025082787942
dc.language.isoen
dc.okm.affiliatedauthorToppari, Jorma
dc.okm.affiliatedauthorDataimport, Lastentautioppi
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherJohn Wiley & Sons
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumbere3777
dc.relation.doi10.1002/dmrr.3777
dc.relation.ispartofjournalDiabetes/Metabolism Research and Reviews
dc.relation.issue2
dc.relation.volume40
dc.source.identifierhttps://www.utupub.fi/handle/10024/191333
dc.titleClinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes
dc.year.issued2024

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Diabetes Metabolism Res - 2024 - Hendriks - Clinical care advice for monitoring of.pdf
Size:
942.25 KB
Format:
Adobe Portable Document Format